Why NovaBridge Biosciences’s (NBP) Stock Is Down 5.47%

By Jenna Brashear
November 21, 2026
Featured Tickers:
NBP

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate NovaBridge Biosciences before investing.

In this article, we go over a few key elements for understanding NovaBridge Biosciences’s stock price such as:

  • NovaBridge Biosciences’s current stock price and volume
  • Why NovaBridge Biosciences’s stock price changed recently
  • Upgrades and downgrades for NBP from analysts
  • NBP’s stock price momentum as measured by its relative strength

About NovaBridge Biosciences (NBP)

Before we jump into NovaBridge Biosciences’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer. The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 clinical trial to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema; ragistomag, which is in Phase 1clinical trial for multiple solid tumors. It has a licensing agreement with AskGene to develop and commercialize VIS-101; collaborations with Bristol Myers Squibb for the development of givastomig; and license and collaboration agreement with AbbVie Ireland Unlimited Company for the development and commercialization of lemzoparlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.

Want to learn more about NovaBridge Biosciences’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about NovaBridge Biosciences.

Learn More About A+ Investor

NovaBridge Biosciences’s Stock Price as of Market Close

As of November 20, 2026, 4:00 PM, CST, NovaBridge Biosciences’s stock price was $0.830.

NovaBridge Biosciences is down 5.66% from its previous closing price of $0.880.

During the last market session, NovaBridge Biosciences’s stock traded between $0.825 and $0.980. Currently, there are approximately 115.72 million shares outstanding for NovaBridge Biosciences.

NovaBridge Biosciences’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

NovaBridge Biosciences Stock Price History

NovaBridge Biosciences’s (NBP) price is currently down 30.54% so far this month.

During the month of November, NovaBridge Biosciences’s stock price has reached a high of $1.210 and a low of $0.751.

Over the last year, NovaBridge Biosciences has hit prices as high as $5.190 and as low as $0.751. Year to date, NovaBridge Biosciences’s stock is down 79.15%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused NovaBridge Biosciences Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 20, 2026, there were analysts who downgraded NovaBridge Biosciences’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate NovaBridge Biosciences’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on NovaBridge Biosciences’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about NovaBridge Biosciences (NBP) by visiting AAII Stock Evaluator.

Relative Price Strength of NovaBridge Biosciences

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 20, 2026, NovaBridge Biosciences has a weighted four-quarter relative price strength of -35.40%, which translates to a Momentum Score of 7 and is considered to be Very Weak.

Want to learn more about how NovaBridge Biosciences is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

NovaBridge Biosciences Stock Price: Bottom Line

As of November 20, 2026, NovaBridge Biosciences’s stock price is $0.830, which is down 5.66% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like NovaBridge Biosciences stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.

Learn More About A+ Investor

Find New Stock Opportunities With Included With AAII Platinum
High Relative Dividend
Yield Screen:
8.7% Compared to S&P 500
at only 6.9%

Since Inception. Data as of 12/31/2024.




Try AAII Platinum and get full access to
769.3% Stock Superstars Portfolio Total Return Since Inception
Compare to:
710.3% iShare DOW Jones
U.S. Index ETF (IYY)

SSR Group 3 O'Shaughnessy portfolio has a 411.2% gain since inception performance compared to IYY at only 119.1%% Performance as of 11/29/24.

Get your free copy of our special report analyzing the tech stocks most likely to outperform the market.

Download the FREE Report Here:

BECOME A MEMBER FOR ONLY $2

Get access to powerful investment discovery tools and a wealth of investment education to help you achieve your financial goals.